The Urologic clinics of North America · 2008
Systemic therapy for metastatic renal cell carcinoma.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kroog Glenn S, Motzer Robert J
Аннотация
Renal cell cancer (RCC) is the most common form of cancer of the kidney and accounts for approximately 44,000 cases per year in the United States. Historically, only immunotherapy showed activity in metastatic RCC. The improved survival and quality of life for patients with metastatic RCC over the last several years are direct results of advances made in understanding the development of RCC. Three targeted therapies-sunitinib, sorafenib, and temsirolimus-have been approved for use in the United States recently. Current research is aimed at developing new drugs and combining available drugs to improve upon the responses and survival seen with approved single agents.
Предметные рубрики MeSH
Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzenesulfonatesBevacizumabCarcinoma, Renal CellCytotoxinsDisease-Free SurvivalDrug Therapy, CombinationEverolimusHumansImmunosuppressive AgentsImmunotherapyIndolesKidney NeoplasmsNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsProtein KinasesPyridinesPyrrolesRandomized Controlled Trials as TopicSirolimusSorafenibStem Cell TransplantationSunitinibTOR Serine-Threonine KinasesTransplantation, Homologous